Armata Pharmaceuticals (FRA:TG1N) Cyclically Adjusted Book per Share: €15.88 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TG1N Armata Pharmaceuticals Inc FRA:TG1N
28 GF Score
Price €3.84
! 5 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals Cyclically Adjusted Book per Share?

Armata Pharmaceuticals FRA:TG1N -5.88% 28 Cyclically Adjusted Book per Share is €15.88 as of Jun. 2026. GuruFocus rates FRA:TG1N with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Armata Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was €-5.443. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €15.88 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Armata Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -72.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 63.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -25.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -53.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Armata Pharmaceuticals was 142.20% per year. The lowest was -82.30% per year. And the median was 2.05% per year.

As of today (2026-09-16), Armata Pharmaceuticals's current stock price is €3.84. Armata Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €15.88. Armata Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.24.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Armata Pharmaceuticals was 0.36. The lowest was 0.01. And the median was 0.01.


Armata Pharmaceuticals  (FRA:TG1N) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Armata Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.84/15.88
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Armata Pharmaceuticals was 0.36. The lowest was 0.01. And the median was 0.01.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Armata Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Armata Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Armata Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Armata Pharmaceuticals Cyclically Adjusted Book per Share Chart

Armata Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.19 96.84 152.42 143.28 108.45

Armata Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.08 39.99 30.23 24.18 15.88

FRA:TG1N vs ACOG, NKTX, CUE: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Armata Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:TG1N
28GF Score
Armata Pharmaceuticals Inc FRA:TG1N
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Armata Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Armata Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-5.443/333.9520*333.9520
=-5.443

Current CPI (Jun. 2026) = 333.9520.

Armata Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 204.201 241.428 282.458
201612 133.753 241.432 185.009
201703 52.779 243.801 72.295
201706 14.158 244.955 19.302
201709 12.390 246.819 16.764
201712 9.489 246.524 12.854
201803 7.806 249.554 10.446
201806 6.072 251.989 8.047
201809 5.016 252.439 6.636
201812 18.587 251.233 24.707
201903 1.887 254.202 2.479
201906 1.995 256.143 2.601
201909 1.674 256.759 2.177
201912 1.310 256.974 1.702
202003 1.637 258.115 2.118
202006 1.416 257.797 1.834
202009 1.125 260.280 1.443
202012 0.825 260.474 1.058
202103 1.160 264.877 1.463
202106 0.968 271.696 1.190
202109 0.821 274.310 1.000
202112 0.824 278.802 0.987
202203 1.532 287.504 1.780
202206 1.411 296.311 1.590
202209 1.287 296.808 1.448
202212 0.935 296.797 1.052
202303 0.572 301.836 0.633
202306 0.486 305.109 0.532
202309 -0.324 307.789 -0.352
202312 -0.804 306.746 -0.875
202403 -1.448 312.332 -1.548
202406 -1.190 314.175 -1.265
202409 -1.262 315.301 -1.337
202412 -1.282 315.605 -1.357
202503 -1.376 319.799 -1.437
202506 -1.636 322.561 -1.694
202509 -2.245 324.800 -2.308
202512 -5.109 324.054 -5.265
202603 -7.423 330.213 -7.507
202606 -5.443 333.952 -5.443

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €15.88 mean?
Armata Pharmaceuticals (FRA:TG1N) has a Cyclically Adjusted Book per Share of €15.88 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Armata Pharmaceuticals and its competitors.
Is Armata Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Armata Pharmaceuticals' current Cyclically Adjusted Book per Share is €15.88. Overall, Armata Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' Cyclically Adjusted Book per Share compare to ACOG and NKTX?
Armata Pharmaceuticals' Cyclically Adjusted Book per Share of €15.88 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Armata Pharmaceuticals and its competitors. Armata Pharmaceuticals's current Cyclically Adjusted Book per Share is €15.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (FRA:TG1N) has a current Cyclically Adjusted Book per Share of €15.88. The current Cyclically Adjusted Book per Share is €15.88. Armata Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Armata Pharmaceuticals (FRA:TG1N), the current Cyclically Adjusted Book per Share is €15.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Armata Pharmaceuticals Business Description

Other Exchanges ARMP:USATG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
28GF Score

Get the complete analysis for FRA:TG1N

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.84
Price